Eckert & Ziegler signed Brazil deal. Eckert & Ziegler stock sits 27.41 percent below its high

Published on 10/19/2026 at 09:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 revenue was EUR 149.3 million. Eckert & Ziegler stock costs EUR 12.87 on October 19, 2026, 0.94 percent above Xetra close.

Radiopharma growth and valuation

A Terbium-161 supply agreement for Brazil was signed on October 13, 2026.
First-half 2026 revenue reached EUR 149.3 million, while adjusted EBIT was EUR 33.3 million.
Eckert & Ziegler stock trades at EUR 12.87 at 9:11 a.m. CEST at Lang & Schwarz on October 19, 2026, 0.94 percent above the Xetra close of October 16, 2026.
The next earnings report is scheduled for November 12, 2026.

Photorealistischer Reinraum einer radiopharmazeutischen Produktionsanlage — Eckert & Ziegler DE0005659700 Medizintechnik: Forscher arbeiten in modernem Radiopharmazeutika-Reinraum mit Gloveboxen und Hot-Cells, Illustration mit AI erstellt.

Eckert & Ziegler (ISIN DE0005659700) was trading at EUR 12.87 at Lang & Schwarz on October 19, 2026 at 9:11 a.m. CEST, 0.94 percent above the Xetra close of October 16, 2026 at EUR 12.75. The company had signed a Terbium-161 supply agreement for Brazil on October 13, according to EQS Group.

Brazil deal expands isotope reach

Under the agreement, TerThera will supply GMP-compliant, non-carrier-added Terbium-161 to Eckert & Ziegler Brazil. The partnership is designed to connect TerThera's isotope production with Eckert & Ziegler's regional distribution and production network, giving Brazilian developers and clinical institutions access to the radiopharmaceutical.

The deal adds a commercial supply element to Eckert & Ziegler's radiopharma strategy. The release describes Terbium-161 as a potential next-generation option for radioligand therapy and links the product to research involving peptides, antibodies and FAP inhibitors.

What supports the earnings case?

The latest reported figures show a mixed but improving operating picture. In the first half of 2026, revenue rose to EUR 149.3 million from EUR 148.8 million, while adjusted EBIT fell to EUR 33.3 million from EUR 35.4 million. Net income increased to EUR 22.4 million from EUR 21.4 million, according to 4investors.

Medical was the stronger segment in that period. Adjusted EBIT rose 7.00 percent to EUR 24.9 million, while group adjusted EBIT declined by nearly 6.00 percent. Management confirmed 2026 guidance for revenue of EUR 320.0 million and adjusted EBIT of EUR 80.0 million.

Three dated milestones shape the picture

On March 26, 2026, management set 2026 guidance at EUR 320.0 million of revenue and EUR 80.0 million of adjusted EBIT. On August 13, 2026, first-half revenue reached EUR 149.3 million and net income EUR 22.4 million, as reported by 4investors. On October 13, 2026, the company signed the Terbium-161 agreement for Brazil.

Key dates for the stock

The next earnings report is scheduled for November 12, 2026, according to TradingView. The next first-quarter 2027 report is listed for May 12, 2027, by Simply Wall St.

Stock remains below its yearly high

The Lang & Schwarz price is EUR 4.86 below the 52-week high of EUR 17.73 and EUR 0.96 above the 52-week low of EUR 11.91. That leaves the market response focused on whether the Brazil agreement and the Terbium-161 pipeline can support the confirmed 2026 earnings plan.

Eckert & Ziegler was trading at EUR 12.87 at Lang & Schwarz on October 19, 2026 at 9:11 a.m. CEST, 0.94 percent above the Xetra close of October 16, 2026 at EUR 12.75. The further course of trading is shown by the continuously updated real-time quote of Eckert & Ziegler stock.